CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
26.49
+1.54 (6.17%)
At close: Aug 13, 2025, 4:00 PM
25.41
-1.08 (-4.08%)
Pre-market: Aug 14, 2025, 8:52 AM EDT
CG Oncology Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for CG Oncology stock ranges from a low of $41 to a high of $75. The average analyst price target of $63.3 forecasts a 138.96% increase in the stock price over the next year.
Price Target: $63.30 (+138.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $68 → $53 | Buy | Maintains | $68 → $53 | +100.08% | Jul 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $52 → $56 | Buy | Maintains | $52 → $56 | +111.40% | Jun 17, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $52 | Buy | Maintains | $55 → $52 | +96.30% | May 19, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +54.78% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $68 | Buy | Maintains | $66 → $68 | +156.70% | Apr 29, 2025 |
Financial Forecast
Revenue This Year
425.56K
from 1.14M
Decreased by -62.64%
Revenue Next Year
108.50M
from 425.56K
Increased by 25,395.55%
EPS This Year
-1.87
from -1.41
EPS Next Year
-1.85
from -1.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.0M | 268.6M | 347.8M | ||
| Avg | 425,564 | 108.5M | 209.0M | ||
| Low | n/a | 19.6M | 122.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 75.2% | 63,004.4% | 220.5% | ||
| Avg | -62.6% | 25,395.6% | 92.6% | ||
| Low | - | 4,505.6% | 12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.65 | -0.88 | 0.62 | ||
| Avg | -1.87 | -1.85 | -0.43 | ||
| Low | -2.16 | -3.51 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.